AGP Executive Report
Last update: 26 minutes agoUK Medical Cannabis: Boots is launching a private prescription service through its online doctor, with reports pointing to treatment for conditions including chronic pain, anxiety and insomnia. Mental Health Research: In a retrospective study of 745 adults receiving transcranial magnetic stimulation for depression, cannabis users improved about as much as non-users; researchers also saw a drop in self-reported use during treatment. Cannabinoid Drug Development: MIRA Pharmaceuticals reported preclinical findings for MIRA-55, an investigational CB2-targeting compound for inflammatory pain. The company says it showed pain-relief and anti-inflammatory effects in preclinical testing; it is not an approved treatment. Psychosis Risk: A review of 149 studies involving more than 71,000 people found cannabis users who developed psychosis experienced its onset about 2.5 years earlier on average. The researchers noted the association does not prove cannabis caused the earlier onset. Hemp Policy: Veterans’ groups are urging Congress to replace an upcoming federal hemp-THC ban with regulation, warning a blanket prohibition could push consumers toward untested products.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.